Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim(Samsung Medical Center), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adam J. Bass(Dana-Farber Cancer Institute), Kyoung‐Mee Kim(Samsung Medical Center), Justin I. Odegaard(Guardant (United States)), Kyung Kim(Samsung Medical Center), Xiao Qiao Liu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Xinwei Sher(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hun Jung(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mi-Jin Lee(Samsung Medical Center), Sujin Lee(Samsung Medical Center), Se Hoon Park(Samsung Medical Center), Joon Oh Park(Samsung Medical Center), Young Suk Park(Samsung Medical Center), Ho Yeong Lim(Samsung Medical Center), Hyuk Lee(Samsung Medical Center), Min Gew Choi(Samsung Medical Center), AmirAli Talasaz(Guardant (United States)), Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeeyun Lee(Samsung Medical Center), Won Ki Kang(Samsung Medical Center)
Nature Medicine
July 13, 2018
Cited by 1,711

Abstract


Related Papers

No related papers found

Powered by citation graph analysis